Zim Laboratories Ltd (ZIMLAB) — shareholding pattern, promoter holding, financials and share price
About Zim Laboratories Ltd (ZIMLAB)
Zim Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ZIMLAB and on the BSE under scrip code 541400. Its ISIN is INE518E01015.
Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India [1]
Zim Laboratories Limited is an Indian formulations manufacturer focused on branded generics, nutraceuticals and innovative delivery platforms—including the Thinoral oral thin film (OTF) technology—and exports a majority of its production to RoW and regulated markets while operating subsidiaries to support international filings and commercialization.
Q3FY26 showed a meaningful operational recovery: Total operating income rose to ₹1,087 million (+12.8% YoY) with EBITDA of ₹145 million and positive PAT of ₹44 million, reflecting sequential margin recovery driven by higher export volumes and a strong uptick in the Nutra business, which grew 93% QoQ in Q3FY26.
Listed peers in Pharmaceuticals: Amanta Healthcare Ltd, Influx Healthtech Ltd, Kilitch Drugs (India) Ltd, Haleos Labs Limited, Jenburkt Pharmaceuticals Ltd, Bafna Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹113.75 a share on 10 Jul 2026, Zim Laboratories Ltd (ZIMLAB) was valued at a price-to-earnings ratio of 104.12x against an industry P/E of 36.41x and a price-to-book of 2.06x on a book value of ₹55.31 per share as of Mar 2026. Solomo computes return on equity of 1.98% and return on capital employed of 5.07% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 104.12x
- Industry P/E
- 36.41x
- P/B
- 2.06x
- EPS (TTM)
- ₹1.09
- Book value / share
- ₹55.31
- ROE
- 1.98%
- ROCE
- 5.07%
- ROA
- 1.08%
- Debt / equity
- 0.43x
- Dividend yield
- 0%
- EBITDA margin
- 11.06%
- 52-week range
- ₹59.72 – ₹133.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Zim Laboratories Ltd (ZIMLAB) reported revenue of ₹374 crore, net profit of ₹6 crore and earnings per share of ₹1.09. That compares with revenue of ₹379 crore and net profit of ₹12 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹105.27 crore and net profit ₹3.74 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 333 | 399 | 367 | 379 | 374 |
| Net profit (₹ cr) | 15 | 24 | 17 | 12 | 6 |
| EPS (₹) | 2.99 | 5.01 | 3.54 | 2.5 | 1.09 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.90% | 4.06% | -2.24% | -1.22% |
| Profit growth | -11.91% | 1.21% | -37.98% | -52.01% |
| Stock price CAGR | - | 20% | 1% | 10% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 30.36% of Zim Laboratories Ltd (ZIMLAB) (up 0.01 pp QoQ), foreign institutional investors (FII) hold 0.03% and domestic institutional investors (DII) hold 1.33%. Market capitalisation was ₹609 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2018.
Largest disclosed public shareholders in Jun 2026: Elimath Advisors Private Limited 10.43%, Zakir S Vali 9.43%, LLP 9.34%, Florintree Trinex Llp 8.9%, Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 3.58%, Bonanza Business Services Pvt Ltd 2.32%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 30.36% | - | 0.03% | 1.33% | 69.64% |
| Mar 2026 | 30.35% | - | - | 0.07% | 69.65% |
| Dec 2025 | 33.26% | - | 0.02% | 0.2% | 66.74% |
| Sep 2025 | 33.26% | - | - | 0.24% | 66.74% |
| Jun 2025 | 33.26% | - | 0.03% | 0.24% | 66.74% |
| Mar 2025 | 33.26% | - | 0.01% | 0.24% | 66.74% |
| Dec 2024 | 33.26% | - | 0.21% | 0.24% | 66.74% |
| Sep 2024 | 33.26% | - | 0% | 0.1% | 66.74% |